Supplemental Preparations in Taxane-Induced Neuropathy Management
-
AmirHosein Sanei
,
Farshad Abedi
,
Mohammad Moeini Nodeh
,
AmirHooshang Mohammadpour
,
Abolghasem Allahyari
,
Fariba Zemorshidi
,
Omid Arasteh
Abstract
Taxane-induced peripheral neuropathy (TIPN) is a dose-limiting adverse effect of chemotherapy without any specific treatment. The aim of this paper is to evaluate the effects of natural products and supplements on TIPN. PubMed, Google Scholar and Web of Science databases were searched through August 2022 regarding TIPN and effects of natural products and supplement therapy. Data consists of preclinical studies, randomized controlled trials and case reports. After screening of 230 papers, we found 13 relevant animal and human studies regarding possible benefits of vitamin E, glutamine, omega-3, acetyl-L-carnitine and group of B vitamins on TIPN. Results demonstrated that vitamin E can be helpful on prevention and duration of TIPN. Glutamine and B vitamins showed hopeful results on reducing pain sensation. Omega-3 also shows promising results on incidence of TIPN. However, acetyl-L-carnitine might develop and worsen neuropathy. Although some supplements revealed promising effects on prevention and treatment of TIPN, researches are still limited and we need further long-term large sample size trials to confirm clinical efficacy of these supplements.
1. Gewandter JS, Kleckner AS, Marshall JH, et al. Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data. Support Care Cancer. 2020;28(6):2553-62.
2. Salehifar E, Janbabaei G, Hendouei N, Alipour A, Tabrizi N, Avan R. Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial. Clin Drug Investig. 2020;40(3):249-57.
3. Song SJ, Min J, Suh SY, et al. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. Support Care Cancer. 2017;25(7):2241-8.
4. Timmins HC, Li T, Kiernan MC, et al. Taxane-induced peripheral neuropathy: differences in patient report and objective assessment. Support Care Cancer. 2020;28(9):4459-66.
5. Pivot X, Koralewski P, Hidalgo J, et al. A multicenter phase II study of XRP6258 administered as a 1-h iv infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19(9):1547-52.
6. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-54.
7. Velasco R, Bruna J. Taxane-induced peripheral neurotoxicity. Toxics. 2015;3(2):152-69.
8. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-oncol. 2012;14(suppl_4):iv45-iv54.
9. Horwitz S. Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994;5:S3-6.
10. Pace A, Bove L, Aloe A, et al. Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients. Ital J Neurol Sci. 1997;18(2):73-9.
11. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82(1):51-77.
12. De Iuliis F, Taglieri L, Salerno G, Lanza R, Scarpa S. Taxane induced neuropathy in patients affected by breast cancer: literature review. Crit Rev Oncol Hematol. 2015;96(1):34-45.
13. Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol. 2011;29(11):1472.
14. Tanabe Y, Hashimoto K, Shimizu C, et al. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol. 2013;18(1):132-8.
15. Flatters SJ, Dougherty PM, Colvin LA. Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review. Brit J Anaesthesia. 2017;119(4):737-49.
16. Raja SN, Haythornthwaite J, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002;59(7):1015-21.
17. Vahdat L, Papadopoulos K, Lange D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res. 2001;7(5):1192-7.
18. Loven D, Levavi H, Sabach G, et al. Long‐term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. Eur J Cancer Care. 2009;18(1):78-83.
19. Hershman DL, Unger JM, Crew KD, et al. Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-L-carnitine (SWOG S0715). J Natl Cancer Inst. 2018;110(6):669-76.
20. Ghoreishi Z, Esfahani A, Djazayeri A, et al. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer. 2012;12(1):1-8.
21. Anoushirvani AA, Poorsaadat L, Aghabozorgi R, Kasravi M. Comparison of the effects of omega 3 and vitamin E on palcitaxel-induced peripheral neuropathy. Open Access Maced J Med Sci. 2018;6(10):1857.
22. Argyriou AA, Chroni E, Koutras A, et al. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. J Pain Symptom Manage. 2006;32(3):237-44.
23. Shamsaei G, Ahmadzadeh A, Mehraban N. The vitamin E preventive effect on Taxol-induced neuropathy among patients with breast cancer: A randomized clinical trial. Jundishapur Journal of Natural Pharmaceutical Products. 2017;12(4); e65027.
24. Heiba MA, Ismail SS, Sabry M, Bayoumy WAE, Kamal KAA. The use of vitamin E in preventing taxane-induced peripheral neuropathy. Cancer Chem Pharmacol. 2021;88(6):931-9.
25. Schloss JM, Colosimo M, Airey C, Masci P, Linnane AW, Vitetta L. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN). Support Care Cancer. 2017;25(1):195-204.
26. Badary O. Effect of acetyl-l-carnitine on the incidence and the severity of paclitaxel-induced peripheral neuropathy in cancer patients. Al-Azhar Journal of Pharmaceutical Sciences. 2014;50(2):14-30.
27. Schloss JM, Colosimo M, Airey C, Vitetta L. Chemotherapy-induced peripheral neuropathy (CIPN) and vitamin B12 deficiency. Support Care Cancer. 2015;23(7):1843-50.
28. Flatters SJ, Xiao W-H, Bennett GJ. Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci Lett. 2006;397(3):219-23.
29. Hamity MV, White SR, Walder RY, Schmidt MS, Brenner C, Hammond DL. Nicotinamide riboside, a form of vitamin B3 and NAD+ precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats. Pain. 2017;158(5):962-72.
30. Smith RJ, Wilmore DW. Glutamine nutrition and requirements. JPEN J Parenter Enteral Nutr. 1990;14:94S-9S.
31. Klimberg VS, McClellan JL. Glutamine, cancer, and its therapy. Am J Surg. 1996;172(5):418-24.
32. Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. J Neural Transm (Vienna). 2014;121(8):799-817.
33. Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinetics. 2003;42(11):941-67.
34. Kris-Etherton PM, Taylor DS, Yu-Poth S, et al. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr. 2000;71(1):179S-88S.
35. L Abner E, A Schmitt F, S Mendiondo M, L Marcum J, J Kryscio R. Vitamin E and all-cause mortality: a meta-analysis. Curr Aging Sci. 2011;4(2):158-70.
36. Tylewicz U, Inchingolo R, Rodriguez-Estrada M. Nutraceutical and Functional Food Components. Elsevier Amsterdam, The Netherlands:; 2017.
37. Carlson K, Ocean AJ. Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin Breast Cancer. 2011;11(2):73-81.
38. Klein I, Lehmann HC. Pathomechanisms of paclitaxel-induced peripheral neuropathy. Toxics. 2021;9(10):229.
39. Fukuda Y, Li Y, Segal RA. A mechanistic understanding of axon degeneration in chemotherapy-induced peripheral neuropathy. Front Neurosci. 2017;11:481.
40. Shim HS, Bae C, Wang J, et al. Peripheral and central oxidative stress in chemotherapy-induced neuropathic pain. Mol Pain. 2019;15:1744806919840098.
41. Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Bol Cell. 2014;25(18):2677-81.
42. Al‐Mazidi S, Alotaibi M, Nedjadi T, Chaudhary A, Alzoghaibi M, Djouhri L. Blocking of cytokines signalling attenuates evoked and spontaneous neuropathic pain behaviours in the paclitaxel rat model of chemotherapy‐induced neuropathy. Eur J Pain. 2018;22(4):810-21.
43. Szklener K, Szklener S, Michalski A, et al. Dietary Supplements in Chemotherapy-Induced Peripheral Neuropathy: A New Hope? Nutrients. 2022;14(3):625.
44. Bae EH, Greenwald MK, Schwartz AG. Chemotherapy-induced peripheral neuropathy: mechanisms and therapeutic avenues. Neurotherapeutics. 2021;18(4):2384-96.
45. Sałat K. Chemotherapy-induced peripheral neuropathy: part 1—current state of knowledge and perspectives for pharmacotherapy. Pharmacol Rep. 2020;72(3):486-507.
46. Brami C, Bao T, Deng G. Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: a systematic review. Crit Rev Oncol Hematol. 2016;98:325-34.
47. Smith EML, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359-67.
48. Otake A, Yoshino K, Ueda Y, et al. Usefulness of duloxetine for Paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients. Anticancer Res. 2015;35(1):359-63.
49. De Santis S, Pace A, Bove L, et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res. 2000;6(1):90-5.
50. Gwag B, Sessler F, Robine V, Springer J. Endogenous glutamate levels regulate nerve growth factor mRNA expression in the rat dentate gyrus. Mol cells. 1997;7(3):425-30.
51. Boyle FM, Wheeler HR, Shenfield GM. Glutamate ameliorates experimental vincristine neuropathy. J Pharmacol Exp Ther. 1996;279(1):410-5.
52. Kandel ER, Schwartz JH, Jessell TM, Siegelbaum S, Hudspeth AJ, Mack S. Principles of neural science: McGraw-hill New York; 2000.
53. Daikhin Y, Yudkoff M. Compartmentation of brain glutamate metabolism in neurons and glia. J Nutr. 2000;130(4):1026S-31S.
54. Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev. 2003;29(6):501-13.
55. Tapiero H, Mathe G, Couvreur P, Tew K. II. Glutamine and glutamate. Biomed Pharmacother. 2002;56(9):446-57.
56. Di Stefano G, Di Lionardo A, Galosi E, Truini A, Cruccu G. Acetyl-L-carnitine in painful peripheral neuropathy: a systematic review. J Pain Res. 2019;12:1341.
57. Lowitt S, Malone J, Salem A, Korthals J, Benford S. Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism. 1995;44(5):677-80.
58. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nature Rev Cancer. 2013;13(11):759-71.
59. Freitas RD, Costa KM, Nicoletti NF, Kist LW, Bogo MR, Campos MM. Omega-3 fatty acids are able to modulate the painful symptoms associated to cyclophosphamide-induced-hemorrhagic cystitis in mice. J Nutr Biochem. 2016;27:219-32.
60. Nakamoto K, Nishinaka T, Sato N, Aizawa F, Yamashita T, Mankura M, et al. The activation of supraspinal GPR 40/FFA 1 receptor signalling regulates the descending pain control system. Brit J Pharmacol. 2015;172(5):1250-62.
61. Freitas RD, Campos MM. Protective effects of omega-3 fatty acids in cancer-related complications. Nutrients. 2019;11(5):945.
62. Kuhad A, Chopra K. Tocotrienol attenuates oxidative–nitrosative stress and inflammatory cascade in experimental model of diabetic neuropathy. Neuropharmacol. 2009;57(4):456-62.
63. Wu F, Xu K, Liu L, et al. Vitamin B12 enhances nerve repair and improves functional recovery after traumatic brain injury by inhibiting ER stress-induced neuron injury. Front Pharmacol. 2019:406.
64. Mondal S, Choudhury KB, Sharma S, Gupta A, Dutta S. Comparative study among glutamine, acetyl-L-carnitine, vitamin-E and methylcobalamine for treatment of paclitaxel-induced peripheral neuropathy. Clin Cancer Investig J. 2014;3(3):213.
2. Salehifar E, Janbabaei G, Hendouei N, Alipour A, Tabrizi N, Avan R. Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial. Clin Drug Investig. 2020;40(3):249-57.
3. Song SJ, Min J, Suh SY, et al. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. Support Care Cancer. 2017;25(7):2241-8.
4. Timmins HC, Li T, Kiernan MC, et al. Taxane-induced peripheral neuropathy: differences in patient report and objective assessment. Support Care Cancer. 2020;28(9):4459-66.
5. Pivot X, Koralewski P, Hidalgo J, et al. A multicenter phase II study of XRP6258 administered as a 1-h iv infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19(9):1547-52.
6. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-54.
7. Velasco R, Bruna J. Taxane-induced peripheral neurotoxicity. Toxics. 2015;3(2):152-69.
8. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-oncol. 2012;14(suppl_4):iv45-iv54.
9. Horwitz S. Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994;5:S3-6.
10. Pace A, Bove L, Aloe A, et al. Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients. Ital J Neurol Sci. 1997;18(2):73-9.
11. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82(1):51-77.
12. De Iuliis F, Taglieri L, Salerno G, Lanza R, Scarpa S. Taxane induced neuropathy in patients affected by breast cancer: literature review. Crit Rev Oncol Hematol. 2015;96(1):34-45.
13. Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol. 2011;29(11):1472.
14. Tanabe Y, Hashimoto K, Shimizu C, et al. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol. 2013;18(1):132-8.
15. Flatters SJ, Dougherty PM, Colvin LA. Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review. Brit J Anaesthesia. 2017;119(4):737-49.
16. Raja SN, Haythornthwaite J, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002;59(7):1015-21.
17. Vahdat L, Papadopoulos K, Lange D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res. 2001;7(5):1192-7.
18. Loven D, Levavi H, Sabach G, et al. Long‐term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. Eur J Cancer Care. 2009;18(1):78-83.
19. Hershman DL, Unger JM, Crew KD, et al. Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-L-carnitine (SWOG S0715). J Natl Cancer Inst. 2018;110(6):669-76.
20. Ghoreishi Z, Esfahani A, Djazayeri A, et al. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer. 2012;12(1):1-8.
21. Anoushirvani AA, Poorsaadat L, Aghabozorgi R, Kasravi M. Comparison of the effects of omega 3 and vitamin E on palcitaxel-induced peripheral neuropathy. Open Access Maced J Med Sci. 2018;6(10):1857.
22. Argyriou AA, Chroni E, Koutras A, et al. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. J Pain Symptom Manage. 2006;32(3):237-44.
23. Shamsaei G, Ahmadzadeh A, Mehraban N. The vitamin E preventive effect on Taxol-induced neuropathy among patients with breast cancer: A randomized clinical trial. Jundishapur Journal of Natural Pharmaceutical Products. 2017;12(4); e65027.
24. Heiba MA, Ismail SS, Sabry M, Bayoumy WAE, Kamal KAA. The use of vitamin E in preventing taxane-induced peripheral neuropathy. Cancer Chem Pharmacol. 2021;88(6):931-9.
25. Schloss JM, Colosimo M, Airey C, Masci P, Linnane AW, Vitetta L. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN). Support Care Cancer. 2017;25(1):195-204.
26. Badary O. Effect of acetyl-l-carnitine on the incidence and the severity of paclitaxel-induced peripheral neuropathy in cancer patients. Al-Azhar Journal of Pharmaceutical Sciences. 2014;50(2):14-30.
27. Schloss JM, Colosimo M, Airey C, Vitetta L. Chemotherapy-induced peripheral neuropathy (CIPN) and vitamin B12 deficiency. Support Care Cancer. 2015;23(7):1843-50.
28. Flatters SJ, Xiao W-H, Bennett GJ. Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci Lett. 2006;397(3):219-23.
29. Hamity MV, White SR, Walder RY, Schmidt MS, Brenner C, Hammond DL. Nicotinamide riboside, a form of vitamin B3 and NAD+ precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats. Pain. 2017;158(5):962-72.
30. Smith RJ, Wilmore DW. Glutamine nutrition and requirements. JPEN J Parenter Enteral Nutr. 1990;14:94S-9S.
31. Klimberg VS, McClellan JL. Glutamine, cancer, and its therapy. Am J Surg. 1996;172(5):418-24.
32. Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. J Neural Transm (Vienna). 2014;121(8):799-817.
33. Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinetics. 2003;42(11):941-67.
34. Kris-Etherton PM, Taylor DS, Yu-Poth S, et al. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr. 2000;71(1):179S-88S.
35. L Abner E, A Schmitt F, S Mendiondo M, L Marcum J, J Kryscio R. Vitamin E and all-cause mortality: a meta-analysis. Curr Aging Sci. 2011;4(2):158-70.
36. Tylewicz U, Inchingolo R, Rodriguez-Estrada M. Nutraceutical and Functional Food Components. Elsevier Amsterdam, The Netherlands:; 2017.
37. Carlson K, Ocean AJ. Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin Breast Cancer. 2011;11(2):73-81.
38. Klein I, Lehmann HC. Pathomechanisms of paclitaxel-induced peripheral neuropathy. Toxics. 2021;9(10):229.
39. Fukuda Y, Li Y, Segal RA. A mechanistic understanding of axon degeneration in chemotherapy-induced peripheral neuropathy. Front Neurosci. 2017;11:481.
40. Shim HS, Bae C, Wang J, et al. Peripheral and central oxidative stress in chemotherapy-induced neuropathic pain. Mol Pain. 2019;15:1744806919840098.
41. Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Bol Cell. 2014;25(18):2677-81.
42. Al‐Mazidi S, Alotaibi M, Nedjadi T, Chaudhary A, Alzoghaibi M, Djouhri L. Blocking of cytokines signalling attenuates evoked and spontaneous neuropathic pain behaviours in the paclitaxel rat model of chemotherapy‐induced neuropathy. Eur J Pain. 2018;22(4):810-21.
43. Szklener K, Szklener S, Michalski A, et al. Dietary Supplements in Chemotherapy-Induced Peripheral Neuropathy: A New Hope? Nutrients. 2022;14(3):625.
44. Bae EH, Greenwald MK, Schwartz AG. Chemotherapy-induced peripheral neuropathy: mechanisms and therapeutic avenues. Neurotherapeutics. 2021;18(4):2384-96.
45. Sałat K. Chemotherapy-induced peripheral neuropathy: part 1—current state of knowledge and perspectives for pharmacotherapy. Pharmacol Rep. 2020;72(3):486-507.
46. Brami C, Bao T, Deng G. Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: a systematic review. Crit Rev Oncol Hematol. 2016;98:325-34.
47. Smith EML, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359-67.
48. Otake A, Yoshino K, Ueda Y, et al. Usefulness of duloxetine for Paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients. Anticancer Res. 2015;35(1):359-63.
49. De Santis S, Pace A, Bove L, et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res. 2000;6(1):90-5.
50. Gwag B, Sessler F, Robine V, Springer J. Endogenous glutamate levels regulate nerve growth factor mRNA expression in the rat dentate gyrus. Mol cells. 1997;7(3):425-30.
51. Boyle FM, Wheeler HR, Shenfield GM. Glutamate ameliorates experimental vincristine neuropathy. J Pharmacol Exp Ther. 1996;279(1):410-5.
52. Kandel ER, Schwartz JH, Jessell TM, Siegelbaum S, Hudspeth AJ, Mack S. Principles of neural science: McGraw-hill New York; 2000.
53. Daikhin Y, Yudkoff M. Compartmentation of brain glutamate metabolism in neurons and glia. J Nutr. 2000;130(4):1026S-31S.
54. Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev. 2003;29(6):501-13.
55. Tapiero H, Mathe G, Couvreur P, Tew K. II. Glutamine and glutamate. Biomed Pharmacother. 2002;56(9):446-57.
56. Di Stefano G, Di Lionardo A, Galosi E, Truini A, Cruccu G. Acetyl-L-carnitine in painful peripheral neuropathy: a systematic review. J Pain Res. 2019;12:1341.
57. Lowitt S, Malone J, Salem A, Korthals J, Benford S. Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism. 1995;44(5):677-80.
58. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nature Rev Cancer. 2013;13(11):759-71.
59. Freitas RD, Costa KM, Nicoletti NF, Kist LW, Bogo MR, Campos MM. Omega-3 fatty acids are able to modulate the painful symptoms associated to cyclophosphamide-induced-hemorrhagic cystitis in mice. J Nutr Biochem. 2016;27:219-32.
60. Nakamoto K, Nishinaka T, Sato N, Aizawa F, Yamashita T, Mankura M, et al. The activation of supraspinal GPR 40/FFA 1 receptor signalling regulates the descending pain control system. Brit J Pharmacol. 2015;172(5):1250-62.
61. Freitas RD, Campos MM. Protective effects of omega-3 fatty acids in cancer-related complications. Nutrients. 2019;11(5):945.
62. Kuhad A, Chopra K. Tocotrienol attenuates oxidative–nitrosative stress and inflammatory cascade in experimental model of diabetic neuropathy. Neuropharmacol. 2009;57(4):456-62.
63. Wu F, Xu K, Liu L, et al. Vitamin B12 enhances nerve repair and improves functional recovery after traumatic brain injury by inhibiting ER stress-induced neuron injury. Front Pharmacol. 2019:406.
64. Mondal S, Choudhury KB, Sharma S, Gupta A, Dutta S. Comparative study among glutamine, acetyl-L-carnitine, vitamin-E and methylcobalamine for treatment of paclitaxel-induced peripheral neuropathy. Clin Cancer Investig J. 2014;3(3):213.
| Files | ||
| Issue | Vol 11, No 1 (Winter 2023) | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/jpc.v11i1.12639 | |
| Keywords | ||
| Chemotherapy;Taxane;Peripheral Neuropathy; Supplements | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Sanei A, Abedi F, Moeini Nodeh M, Mohammadpour A, Allahyari A, Zemorshidi F, Arasteh O. Supplemental Preparations in Taxane-Induced Neuropathy Management. J Pharm Care. 2023;11(1):40-53.
